PRECLINICAL DEVELOPMENT OF THE PI3K ALPHA SELECTIVE AND PIK3CA MUTANT SELECTIVE INHIBITOR GDC-0077 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS

被引：0
|
作者：
Pang, Jodie [1 ]
Baumgardner, Matthew [1 ]
Braun, Marie-Gabrielle [1 ]
Cheong, Jonathan [1 ]
Edgar, Kyle [1 ]
Friedman, Lori [1 ]
Hanan, Emily [1 ]
Jaochico, Allan [1 ]
Ma, Shuguang [1 ]
Plise, Emile [1 ]
Schmidt, Stephen [1 ]
Liu, Ning [1 ]
Song, Kyung [1 ]
Staben, Steve [1 ]
Salphati, Laurent [1 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2019年 / 34卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P56
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [31] Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.
    Jhaveri, Komal L.
    Bedard, Philippe L.
    Cejalvo, Juan Miguel
    Hart, Lowell L.
    Juric, Dejan
    Kelly, Karen
    Lockhart, A. Craig
    Melnyk, Anton
    Moore, Kathleen N.
    Nemunaitis, John J.
    Oliveira, Mafalda
    Patel, Manish R.
    Sachdev, Jasgit
    Smith, David
    VanderWalde, Ari
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Discovery of a novel and potent mutant-selective inhibitor of PI3Kα
    Gao, Mingming
    Qi, Chao
    Li, Zhentian
    Fan, Qipeng
    Wang, Liyang
    Zhou, Fei
    You, Lin
    Zheng, Hewen
    Li, Yu
    Wu, Liangxing
    Yao, Wenqing
    Liu, Phillip C.
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Preclinical characterization of a novel PI3Kα H1047R mutant-selective inhibitor
    Smith, A. C.
    Arwood-Levine, B.
    Born, A.
    Chatterjee, P.
    Chicarelli, M. J.
    Conner, M. L.
    Fulton, J.
    Hubert, H.
    Knox, H.
    Mclean, B.
    Nassar, K. W.
    Newhouse, B.
    Niman, S.
    Stunkard, L.
    Sutter, P.
    Turton, R.
    Van Gulick, R.
    Venteicher, B.
    Vine, L.
    Zhou, Y.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S59 - S59
  • [34] CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
    Vora, Sadhna R.
    Juric, Dejan
    Kim, Nayoon
    Mino-Kenudson, Mari
    Huynh, Tiffany
    Costa, Carlotta
    Lockerman, Elizabeth L.
    Pollack, Sarah F.
    Liu, Manway
    Li, Xiaoyan
    Lehar, Joseph
    Wiesmann, Marion
    Wartmann, Markus
    Chen, Yan
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Kim, Sunkyu
    Schlegel, Robert
    Huang, Alan
    Engelman, Jeffrey A.
    CANCER CELL, 2014, 26 (01) : 136 - 149
  • [35] Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
    Tyler, Foley
    Payne, Susan
    Yeuh, Alexander
    Van DeHey, Dana
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
    Payne, Susan
    Foley, Tyler
    Pasch, Cheri
    Yueh, Alexander
    Korkos, Demetra
    Van De Hey, Dana
    Clipson, Linda
    Deming, Dustin
    CANCER RESEARCH, 2016, 76
  • [37] Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
    Sutherlin, Daniel P.
    Belvin, Marcia
    Bao, Linda
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Edgar, Kyle
    Folkes, Adrian
    Friedman, Lori
    Heffron, Tim
    Patel, Sonal
    Olivero, Alan
    Lesnick, John
    Lewis, Cristina
    Marsters, James
    Nonomiya, Jim
    Pang, Jodie
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Tsui, Vickie
    Wallin, Jeff
    Wei, BinQing
    Weismann, Christian
    Zhu, Bing-Yan
    CANCER RESEARCH, 2011, 71
  • [38] PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway
    Guan, Ruijuan
    Kang, Zefeng
    Li, Ling
    Yan, Xin
    Gao, Tianpeng
    PLOS ONE, 2024, 19 (01):
  • [39] Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer
    Savage, Heidi M.
    O'Brien, Carol
    Yauch, Bob
    Settleman, Jeff
    Lackner, Mark R.
    Wilson, Timothy R.
    CANCER RESEARCH, 2014, 74 (19)
  • [40] PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC
    Heavey, S.
    Davies, M. A.
    O'Byrne, K. J.
    Gately, K.
    LUNG CANCER, 2013, 79 : S3 - S3
12345